Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

Anti-Cancer Agents in Medicinal Chemistry, 14(5): 646-650.

Author(s): Antonio Passaro, Daniele Alesini, Alessia Pochesci and Enrico Cortesi.

Affiliation: Division of Medical Oncology, Sapienza – University of Rome, Viale Regina Elena, 324 - 00161, Rome, Italy.


Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.


EGFR, elderly, erlotinib, gefitinib, non-small-cell lung cancer, tyrosine kinase inhibitor.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 5
First Page: 646
Last Page: 650
Page Count: 5
DOI: 10.2174/187152061405140501101624
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science